WG Critical Care

What WG Critical Care does

WG Critical Care, LLC is a Paramus, New Jersey-based, privately held specialty pharmaceutical company founded in 1982 and operating as a wholly owned subsidiary of PharmaSphere, Inc. The company develops, manufactures, and distributes an expanding portfolio of 30+ FDA-approved generic injectable pharmaceuticals organized across five therapeutic categories: anti-infectives (e.g., Ampicillin, Cefazolin, Cefepime, Ceftriaxone, Meropenem, Piperacillin/Tazobactam), cardiovascular agents (Esmolol, Diltiazem, Norepinephrine, Nicardipine), sedatives (Dexmedetomidine, Midazolam), oncology products (Cisplatin, Paclitaxel, Teniposide), and electrolytes (Calcium Gluconate, Magnesium Sulfate). The company's technology centers on ready-to-use (RTU) premixed bag and sterile powder vial formulations featuring extended shelf life (up to 36 months at controlled room temperature), 60-day stability outside overwrap, DEHP/PVC/latex-free containers, and unit-of-use barcoding aligned with Drug Supply Chain Security Act requirements. Several products are explicitly positioned as 'First and Only' FDA-approved RTU formulations, including Calcium Gluconate in Sodium Chloride, Midazolam in 0.9% Sodium Chloride, and Esmolol HCl in WFI.

The business is a sales-led B2B operation distributing through major pharmaceutical wholesalers and direct customer service ordering to hospitals, specialty markets, and alternate site healthcare settings across the United States. Revenue is generated through one-time sales of injectable pharmaceuticals at undisclosed wholesale prices; no external institutional investment, venture funding, or public listing is identified, and the company operates under a wholly subsidiary structure of PharmaSphere, Inc. The company also operates an Animal Health Division (Quartermaster Suspension, Masti-Clear, go-dry), and has contractual restrictions barring sale of certain products to penal institutions for use in lethal injections.

Name

WG Critical Care

Legal name

WG Critical Care, LLC

Website

https://wgcriticalcare.com

Company type

Private

Founded year

1982

Operating status

Operating

Headcount range

11–50 employees

Short description

WG Critical Care is a US generic injectable pharmaceutical manufacturer serving hospitals and alternate site healthcare settings with 30+ FDA-approved products, including first-to-market ready-to-use formulations for critical care medications.

Ownership category

akta.pro rank

Headquarters

HQ city

Paramus

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Injectable Pharmaceuticals Sales: WG Critical Care generates revenue through the sale of FDA-approved generic injectable pharmaceuticals to hospitals, specialty markets, and alternate site healthcare settings. Products are sold through wholesalers and direct ordering.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

WG Critical Care is a specialty pharmaceutical manufacturer that develops, produces, and distributes more than 30 injectable pharmaceutical products used in hospital and critical care settings. Its portfolio spans Anti-Infectives, Cardiovascular Agents, Sedatives, Oncology, and Electrolytes, and it also operates an Animal Health Division serving veterinary channels.

Product overview

WG Critical Care is a pharmaceutical company specializing in injectable medications for hospital and critical care settings. The product portfolio consists of 30+ essential injectable drug products organized by therapeutic category: Anti-Infectives (antibiotics including Ampicillin, Cefazolin, Cefepime, Ceftriaxone, Meropenem, Piperacillin/Tazobactam), Cardiovascular Agents (Esmolol, Diltiazem, Norepinephrine, Nicardipine), Sedatives (Dexmedetomidine, Midazolam), Oncology (Cisplatin, Paclitaxel, Teniposide), and Electrolytes (Calcium Gluconate, Magnesium Sulfate). Many products are offered in ready-to-use bag formulations that address drug shortages and improve clinical efficiency. The company also maintains an Animal Health division with products like Quartermaster Suspension, Masti-Clear, and go-dry. Products are distributed through wholesalers and direct customer service, with barcoding on unit-of-use packaging.

Differentiator

Problem solved

Functional benefit

Brands

• Novaplus: Private label brand for Cefoxitin for Injection, USP products marketed under the Novaplus designation.

Products and services

• Anti-Infective Injectable Pharmaceuticals

Quantifiable outcome

• Extended shelf life of 36 months at controlled room temperature for Calcium Gluconate products
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• PharmaSphere, Inc.coreOthers · 11 October 2016WG Critical Care, LLC is a wholly owned subsidiary of PharmaSphere, Inc. The company operates as part of the PharmaSphere corporate family, with PharmaSphere providing strategic direction and corporate oversight. WGCC is described as a fully integrated pharmaceutical company under the PharmaSphere umbrella.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• B. Braun Medical: Global medical device and pharmaceutical company with a substantial US injectable pharmaceutical business serving hospitals. Highly comparable: same product format (sterile injectable generics and IV solutions), same customer base (US hospitals), same wholesale distribution. Direct competitor in IV admixture and critical care injectables.
• Sagent Pharmaceuticals: US-based specialty injectable pharmaceutical company focused on hospital and acute care markets. Highly comparable: same business model (specialty injectable generics for US hospitals), same distribution via wholesalers, same product categories (anti-infectives, cardiovascular). Acquired by Nichi-Iko in 2019, providing a comparable exit template.
• Sandoz (Novartis): Global leader in generic pharmaceuticals with a major US injectable business. Highly comparable: same product format (sterile injectable generics), same customer base (US hospitals), same therapeutic categories. Direct competitor on multiple WGCC products including anti-infectives, cardiovascular, and oncology injectables.
• Fresenius Kabi: Global pharmaceutical company specializing in injectable pharmaceuticals and IV infusion therapies for hospitals. Highly comparable: same product format (sterile injectable generics), same therapeutic categories (anti-infectives, anesthetics, critical care), same customer base (US hospitals). One of the largest direct competitors in generic injectables.
• Exela Pharma Sciences: US-based specialty injectable pharmaceutical company focused on critical care and hospital injectables. Highly comparable: same business model (specialty injectable generics for US hospitals), similar product categories (anti-infectives, cardiovascular, oncology), same emphasis on addressing drug shortages. Closest mid-size competitor in terms of positioning and scale.
• Teva Pharmaceutical Industries: Global pharmaceutical company with substantial US generic injectable business. Highly comparable: same product format, same customer base, same go-to-market via wholesalers. Direct competitor on anti-infectives, oncology, and other hospital injectable categories.
• Aurobindo Pharma USA: US arm of Aurobindo Pharma, a major Indian generic manufacturer with substantial US injectable presence. Highly comparable: same product format (sterile injectable generics), same customer base (US hospitals), same wholesale distribution. Direct competitor on anti-infectives (meropenem, cephalosporins) and other critical care injectables.
• Hikma Pharmaceuticals: Global specialty pharmaceutical company with a major injectable generics business serving US hospitals. Highly comparable: same target customers (US hospitals), same product format (sterile injectable generics), same therapeutic categories (anti-infectives, cardiovascular, oncology). Direct head-to-head competitor on multiple WGCC portfolio products.
• Amphastar Pharmaceuticals: US-based specialty injectable pharmaceutical company focused on generic injectables, inhalation, and intranasal products. Highly comparable: same business model (specialty injectables via wholesalers), same customer base (hospitals), same competitive dynamic (first-to-market RTU formulations). Overlaps directly on products like Enoxaparin and other hospital injectables.
• Pfizer Injectables (formerly Hospira): Injectables arm of Pfizer, the largest US sterile injectable manufacturer. Highly comparable: same product format, same hospital customer base, deep RTU/premixed portfolio. Direct competitor on products like Dexmedetomidine (Precedex), Meropenem, and the broader anti-infective and cardiovascular injectable categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WG Critical Care